{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:32:05Z","timestamp":1790015525909,"version":"4.0.1"},"reference-count":114,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clml.2021.07.013","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T09:52:56Z","timestamp":1626601976000},"page":"812-822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma"],"prefix":"10.1016","volume":"21","author":[{"given":"Laeth L.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa N.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razwana","family":"Khanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Saterehaseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"McNichol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.013_bib0001","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.amjmed.2006.10.018","article-title":"Frailty: an emerging geriatric syndrome","volume":"120","author":"Ahmed","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0002","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2021.07.013_bib0003","first-page":"27100","article-title":"Are we making progress? Survival in plasma cell malignancies in the era of novel treatments a population based study of 17.790 patients in The Netherlands. Haematologica","volume":"4","author":"Verelst","year":"2012"},{"key":"10.1016\/j.clml.2021.07.013_bib0004","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1049909116646337","article-title":"Self-reported quality of life and symptom burden in ambulatory patients with multiple myeloma on disease-modifying treatment","volume":"34","author":"Kiely","year":"2017","journal-title":"Am J Hospice Pall Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0005","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/pds.3927","article-title":"Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model","volume":"25","author":"Ruzafa","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clml.2021.07.013_bib0006","unstructured":"Altekruse S. SEER cancer statistics review, 1975-2007. http:\/\/seer cancer gov\/csr\/1975_2007\/results_merged\/sect_13_leukemia pdf. 2009."},{"key":"10.1016\/j.clml.2021.07.013_bib0007","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.013_bib0008","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ctrv.2014.12.010","article-title":"A systematic review of factors influencing older adults' decision to accept or decline cancer treatment","volume":"41","author":"Puts","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2021.07.013_bib0009","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bjh.14033","article-title":"Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study","volume":"174","author":"Buckstein","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0010","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","article-title":"The prevalence and outcomes of frailty in older cancer patients: a systematic review","volume":"26","author":"Handforth","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.07.013_bib0011","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol Ser A Biol Sci Med Sci"},{"key":"10.1016\/j.clml.2021.07.013_bib0012","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0021-9681(78)90058-9","article-title":"A questionnaire for the assessment of leisure time physical activities","volume":"31","author":"Taylor","year":"1978","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clml.2021.07.013_bib0013","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jgo.2018.10.010","article-title":"Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older","volume":"10","author":"Murillo","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clml.2021.07.013_bib0014","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.013_bib0015","unstructured":"National Comprehensive Cancer Network. Multiple Myeloma. Accessed January 21, 2021 [Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"key":"10.1016\/j.clml.2021.07.013_bib0016","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2021.07.013_bib0017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.07.013_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and functional changes with the aging kidney","volume":"23","author":"Denic","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.clml.2021.07.013_bib0019","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1681\/ASN.2014090876","article-title":"ESRD due to multiple myeloma in the United States, 2001\u20132010","volume":"27","author":"Reule","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2021.07.013_bib0020","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/archinternmed.2010.415","article-title":"Early start of hemodialysis may be harmful","volume":"171","author":"Rosansky","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0021","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1080\/10428194.2016.1277385","article-title":"Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study","volume":"58","author":"de Vries","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.013_bib0022","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.24335","article-title":"Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis","volume":"91","author":"Dimopoulos","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0023","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.013_bib0024","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00277-011-1401-2","article-title":"Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment","volume":"91","author":"Song","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0026","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/sj.bmt.1700950","article-title":"High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency","volume":"20","author":"Ballester","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.07.013_bib0027","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.013_bib0028","doi-asserted-by":"crossref","first-page":"e961","DOI":"10.1016\/j.clml.2020.07.015","article-title":"Modified hyper-CVAD with proteasome inhibition for multiple myeloma: a single-center retrospective analysis","volume":"20","author":"Narayan","year":"2020","journal-title":"Clin Lymph Myel Leuk"},{"issue":"17","key":"10.1016\/j.clml.2021.07.013_bib0029","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clml.2015.12.007","article-title":"Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study","volume":"16","author":"Berdeja","year":"2016","journal-title":"Clin Lymph Myel Leuk"},{"key":"10.1016\/j.clml.2021.07.013_bib0031","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.14125","article-title":"A pharmacokinetics and safety phase 1\/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis","volume":"174","author":"Gupta","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0032","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2215\/CJN.06100616","article-title":"Renal toxicities of novel agents used for treatment of multiple myeloma","volume":"12","author":"Wanchoo","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2021.07.013_bib0033","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.013_bib0034","unstructured":"UpToDate. Treatment protocols for multiple myeloma November 24,2020 [Available at: https:\/\/www.uptodate.com\/contents\/treatment-protocols-for-multiple-myeloma?search=multiple%20myeloma%20treatment&source=search_result&selectedTitle=3\u223c150&usage_type=default&display_rank=3."},{"key":"10.1016\/j.clml.2021.07.013_bib0035","article-title":"Selinexor efficacy and safety are independent of renal function in patients with relapsed\/refractory diffuse large b-cell lymphoma (DLBCL): a post-hoc analysis from the Pivotal Phase 2b Sadal Study","author":"Michael","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.013_bib0036","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2215\/CJN.04590908","article-title":"Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis","volume":"4","author":"Hutchison","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2021.07.013_bib0037","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2021.07.013_bib0038","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.00510109","article-title":"Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease?","volume":"4","author":"Carson","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2021.07.013_bib0039","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/08860220701459634","article-title":"Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis","volume":"29","author":"Wong","year":"2007","journal-title":"Ren Fail"},{"key":"10.1016\/j.clml.2021.07.013_bib0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0041","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.013_bib0042","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"10.1016\/j.clml.2021.07.013_bib0043","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.013_bib0044","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0045","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0046","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.013_bib0047","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet North Am Ed"},{"issue":"12","key":"10.1016\/j.clml.2021.07.013_bib0048","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2021.07.013_bib0049","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2021.07.013_bib0050","series-title":"Bisphosphonate [Updated 2020 Jul 4] [In: StatPearls [Internet]","author":"Ganesan","year":"2020"},{"key":"10.1016\/j.clml.2021.07.013_bib0051","unstructured":"UpToDate. Bisphosphonates: drug information 2020, November 15 [Available at: https:\/\/www.uptodate.com\/contents\/alendronate-drug-information?search=bisphosphonates&selectedTitle=1\u223c133&usage_type=panel&display_rank=1&kp_tab=drug_general&source=panel_search_result#F131409."},{"key":"10.1016\/j.clml.2021.07.013_bib0052","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jpc.13768","article-title":"Consensus guidelines on the use of bisphosphonate therapy in children and adolescents","volume":"54","author":"Simm","year":"2018","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.clml.2021.07.013_bib0053","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/1060028016649368","article-title":"Identification of risk factors for bisphosphonate-associated atypical femoral fractures and osteonecrosis of the jaw in a pharmacovigilance database","volume":"50","author":"Bejhed","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clml.2021.07.013_bib0054","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jebdp.2017.11.002","article-title":"Recommendations for the prevention of bisphosphonate-related osteonecrosis of the jaw: a systematic review","volume":"18","author":"Aparecida Cariolatto","year":"2018","journal-title":"J Evidence-Based Dent Pract"},{"key":"10.1016\/j.clml.2021.07.013_bib0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2021.07.013_bib0056","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.013_bib0057","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJMoa0900429","article-title":"A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures","volume":"361","author":"Buchbinder","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0058","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa0900563","article-title":"A randomized trial of vertebroplasty for osteoporotic spinal fractures","volume":"361","author":"Kallmes","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0059","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hon.2486","article-title":"Role of BMI and age in predicting pathologic vertebral fractures in newly diagnosed multiple myeloma patients: a retrospective cohort study","volume":"36","author":"Chen","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2021.07.013_bib0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ejh.13009","article-title":"Falls in older adults with multiple myeloma","volume":"100","author":"Wildes","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0061","article-title":"Exercise for preventing falls in older people living in the community","volume":"1","author":"Sherrington","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2021.07.013_bib0062","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1016\/j.apmr.2018.04.008","article-title":"Efficacy of exercise interventions in patients with advanced cancer: a systematic review","volume":"99","author":"Heywood","year":"2018","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.clml.2021.07.013_bib0063","first-page":"711","article-title":"Initiating exercise interventions to promote wellness in cancer patients and survivors","volume":"31","author":"Schwartz","year":"2017","journal-title":"Oncology (Williston Park, NY)"},{"key":"10.1016\/j.clml.2021.07.013_bib0064","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.013_bib0065","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.013_bib0066","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2021.07.013_bib0067","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0068","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1002\/ajh.25658","article-title":"Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score","volume":"95","author":"Chalayer","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0069","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1212\/WNL.0b013e31829e701d","article-title":"Anemia and risk of dementia in older adults: findings from the Health ABC study","volume":"81","author":"Hong","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2021.07.013_bib0070","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.013_bib0071","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.amjmed.2017.10.036","article-title":"Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial","volume":"131","author":"Rao","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0072","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1007\/s00268-018-4728-1","article-title":"Recurrent falls among elderly patients and the impact of anticoagulation therapy","volume":"42","author":"Chiu","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.clml.2021.07.013_bib0073","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","article-title":"Risk of falls and major bleeds in patients on oral anticoagulation therapy","volume":"125","author":"Donz\u00e9","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0074","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00277-014-2155-4","article-title":"Prevalence of anemia and its impact on the state of frailty in elderly people living in the community: SADEM study","volume":"93","author":"Ju\u00e1rez-Cedillo","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0075","first-page":"211","article-title":"[Profile and prognosis of patients over 85 years old with anemia living in the community. Octabaix Study].","volume":"50","author":"Contreras Mdel","year":"2015","journal-title":"Rev espanola Geriatr Gerontol"},{"key":"10.1016\/j.clml.2021.07.013_bib0076","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/0891988711417132","article-title":"Anemia associated with depressive symptoms in mild cognitive impairment with severe white matter hyperintensities","volume":"24","author":"Son","year":"2011","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.clml.2021.07.013_bib0077","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.23336","article-title":"Hemoglobin decline, function, and mortality in the elderly: the cardiovascular health study","volume":"88","author":"Zakai","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0078","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra1612789","article-title":"Indications for and adverse effects of red-cell transfusion","volume":"377","author":"Carson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0079","article-title":"Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion","volume":"10","author":"Carson","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2021.07.013_bib0080","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00277-017-2950-9","article-title":"Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study","volume":"96","author":"Castelli","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0081","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.013_bib0082","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2017.02.025","article-title":"Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial","volume":"17","author":"Branagan","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.07.013_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6803a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season","volume":"68","author":"Grohskopf","year":"2019","journal-title":"MMWR Recommend Rep"},{"key":"10.1016\/j.clml.2021.07.013_bib0084","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clml.2021.07.013_bib0085","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clml.2021.07.013_bib0086","doi-asserted-by":"crossref","unstructured":"Bennett NM, Whitney CG, Moore M, Pilishvili T, Dooling KL. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). 2012.","DOI":"10.1111\/ajt.12073"},{"key":"10.1016\/j.clml.2021.07.013_bib0087","first-page":"1","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","author":"Ludwig","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.013_bib0088","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2021.07.013_bib0089","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1542\/peds.67.2.222","article-title":"Immunity to diphtheria, pertussis, tetanus, and poliomyelitis in children with acute lymphocytic leukemia after cessation of chemotherapy","volume":"67","author":"Hermans","year":"1981","journal-title":"Pediatrics"},{"key":"10.1016\/j.clml.2021.07.013_bib0090","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.013_bib0091","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0609.1989.tb01250.x","article-title":"Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease","volume":"43","author":"Frederiksen","year":"1989","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0092","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2021.07.013_bib0093","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6703a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season","volume":"67","author":"Grohskopf","year":"2018","journal-title":"MMWR Recommend Rep"},{"key":"10.1016\/j.clml.2021.07.013_bib0094","first-page":"301","article-title":"Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience","volume":"23","author":"Cerchione","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2021.07.013_bib0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/10245332.2018.1538001","article-title":"The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments","volume":"24","author":"Benbrahim","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2021.07.013_bib0096","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0097","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0098","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0099","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.013_bib0100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","article-title":"Treatment of multiple myeloma","volume":"103","author":"Barlogie","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.013_bib0101","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clml.2021.07.013_bib0102","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1080\/10428194.2018.1429605","article-title":"Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors","volume":"59","author":"Leng","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.013_bib0103","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","article-title":"Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations","volume":"34","author":"Girmenia","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2021.07.013_bib0104","first-page":"423","article-title":"Multiple myeloma in the very elderly patient: challenges and solutions","volume":"11","author":"Willan","year":"2016","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.clml.2021.07.013_bib0105","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","article-title":"How I manage the toxicities of myeloma drugs","volume":"129","author":"Delforge","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.013_bib0106","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2021.07.013_bib0107","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.013_bib0108","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.013_bib0109","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12185-014-1672-1","article-title":"Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens","volume":"100","author":"Jung","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2021.07.013_bib0110","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clml.2021.07.013_bib0111","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/jac\/dkt129","article-title":"Community-associated Clostridium difficile infection and antibiotics: a meta-analysis","volume":"68","author":"Deshpande","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clml.2021.07.013_bib0112","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1503\/cmaj.050978","article-title":"Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec","volume":"173","author":"P\u00e9pin","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.clml.2021.07.013_bib0113","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/375078","article-title":"Fluoroquinolone-associated tendinopathy: a critical review of the literature","volume":"36","author":"Khaliq","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2021.07.013_bib0114","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.amjmed.2012.05.027","article-title":"Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders","volume":"125","author":"Wise","year":"2012","journal-title":"Am J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:09Z","timestamp":1761871089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":114,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2152265021002846"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}